Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study
OBJECTIVES: To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA). METHODS: From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and...
Published in: | Rheumatology |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://vbn.aau.dk/da/publications/7ceece47-dc50-491e-9845-b8c0f9016c52 https://doi.org/10.1093/rheumatology/keaa828 |
id |
ftalborgunivpubl:oai:pure.atira.dk:publications/7ceece47-dc50-491e-9845-b8c0f9016c52 |
---|---|
record_format |
openpolar |
spelling |
ftalborgunivpubl:oai:pure.atira.dk:publications/7ceece47-dc50-491e-9845-b8c0f9016c52 2024-10-13T14:08:29+00:00 Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study Hellgren, Karin Ballegaard, Christine Delcoigne, Bénédicte Cordtz, René Nordström, Dan Aaltonen, Kalle Gudbjornsson, Bjorn Love, Thorvardur Jon Aarrestad Provan, Sella Sexton, Joe Zobbe, Kristian Kristensen, Lars Erik Askling, Johan Dreyer, Lene 2021-08-02 https://vbn.aau.dk/da/publications/7ceece47-dc50-491e-9845-b8c0f9016c52 https://doi.org/10.1093/rheumatology/keaa828 eng eng https://vbn.aau.dk/da/publications/7ceece47-dc50-491e-9845-b8c0f9016c52 info:eu-repo/semantics/closedAccess Hellgren , K , Ballegaard , C , Delcoigne , B , Cordtz , R , Nordström , D , Aaltonen , K , Gudbjornsson , B , Love , T J , Aarrestad Provan , S , Sexton , J , Zobbe , K , Kristensen , L E , Askling , J & Dreyer , L 2021 , ' Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study ' , Rheumatology , vol. 60 , no. 8 , pp. 3656-3668 . https://doi.org/10.1093/rheumatology/keaa828 cancer arthritis psoriatic denmark prostate-specific antigen rheumatology tumor necrosis factor inhibitors article 2021 ftalborgunivpubl https://doi.org/10.1093/rheumatology/keaa828 2024-09-19T00:52:41Z OBJECTIVES: To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA). METHODS: From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and ICEBIO (Iceland) we identified PsA patients who started a first TNFi 2001-2017 (n = 9655). We identified patients with PsA not treated with biologics from (i) the CRR (n = 14 809) and (ii) the national patient registers (PR, n = 31 350). By linkage to the national cancer registers, we collected information on incident solid cancer overall and for eight cancer types. We used Cox regression to estimate hazard ratio (HR) with 95% CI of cancer (per country and pooled) in TNFi-exposed vs biologics-naïve, adjusting for age, sex, calendar period, comorbidities and disease activity. We also assessed standardized incidence ratios (SIR) in TNFi-exposed PsA vs the general population (GP). RESULTS: We identified 296 solid cancers among the TNFi-exposed PsA patients (55 850 person-years); the pooled adjusted HR for solid cancer overall was 1.0 (0.9-1.2) for TNFi-exposed vs biologics-naïve PsA from the CRR, and 0.8 (0.7-1.0) vs biologics-naïve PsA from the PRs. There were no significantly increased risks for any of the cancer types under study. The pooled SIR of solid cancer overall in TNFi treated PsA vs GP was 1.0 (0.9-1.1). CONCLUSION: In this large cohort study from five Nordic countries, we found no increased risk of solid cancer in TNFi-treated PsA patients, neither for solid cancer overall nor for eight common cancer types. Article in Journal/Newspaper Iceland Aalborg University's Research Portal Norway Rheumatology |
institution |
Open Polar |
collection |
Aalborg University's Research Portal |
op_collection_id |
ftalborgunivpubl |
language |
English |
topic |
cancer arthritis psoriatic denmark prostate-specific antigen rheumatology tumor necrosis factor inhibitors |
spellingShingle |
cancer arthritis psoriatic denmark prostate-specific antigen rheumatology tumor necrosis factor inhibitors Hellgren, Karin Ballegaard, Christine Delcoigne, Bénédicte Cordtz, René Nordström, Dan Aaltonen, Kalle Gudbjornsson, Bjorn Love, Thorvardur Jon Aarrestad Provan, Sella Sexton, Joe Zobbe, Kristian Kristensen, Lars Erik Askling, Johan Dreyer, Lene Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study |
topic_facet |
cancer arthritis psoriatic denmark prostate-specific antigen rheumatology tumor necrosis factor inhibitors |
description |
OBJECTIVES: To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA). METHODS: From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and ICEBIO (Iceland) we identified PsA patients who started a first TNFi 2001-2017 (n = 9655). We identified patients with PsA not treated with biologics from (i) the CRR (n = 14 809) and (ii) the national patient registers (PR, n = 31 350). By linkage to the national cancer registers, we collected information on incident solid cancer overall and for eight cancer types. We used Cox regression to estimate hazard ratio (HR) with 95% CI of cancer (per country and pooled) in TNFi-exposed vs biologics-naïve, adjusting for age, sex, calendar period, comorbidities and disease activity. We also assessed standardized incidence ratios (SIR) in TNFi-exposed PsA vs the general population (GP). RESULTS: We identified 296 solid cancers among the TNFi-exposed PsA patients (55 850 person-years); the pooled adjusted HR for solid cancer overall was 1.0 (0.9-1.2) for TNFi-exposed vs biologics-naïve PsA from the CRR, and 0.8 (0.7-1.0) vs biologics-naïve PsA from the PRs. There were no significantly increased risks for any of the cancer types under study. The pooled SIR of solid cancer overall in TNFi treated PsA vs GP was 1.0 (0.9-1.1). CONCLUSION: In this large cohort study from five Nordic countries, we found no increased risk of solid cancer in TNFi-treated PsA patients, neither for solid cancer overall nor for eight common cancer types. |
format |
Article in Journal/Newspaper |
author |
Hellgren, Karin Ballegaard, Christine Delcoigne, Bénédicte Cordtz, René Nordström, Dan Aaltonen, Kalle Gudbjornsson, Bjorn Love, Thorvardur Jon Aarrestad Provan, Sella Sexton, Joe Zobbe, Kristian Kristensen, Lars Erik Askling, Johan Dreyer, Lene |
author_facet |
Hellgren, Karin Ballegaard, Christine Delcoigne, Bénédicte Cordtz, René Nordström, Dan Aaltonen, Kalle Gudbjornsson, Bjorn Love, Thorvardur Jon Aarrestad Provan, Sella Sexton, Joe Zobbe, Kristian Kristensen, Lars Erik Askling, Johan Dreyer, Lene |
author_sort |
Hellgren, Karin |
title |
Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study |
title_short |
Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study |
title_full |
Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study |
title_fullStr |
Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study |
title_full_unstemmed |
Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study |
title_sort |
risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with tnf inhibitors - a nordic cohort study |
publishDate |
2021 |
url |
https://vbn.aau.dk/da/publications/7ceece47-dc50-491e-9845-b8c0f9016c52 https://doi.org/10.1093/rheumatology/keaa828 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Hellgren , K , Ballegaard , C , Delcoigne , B , Cordtz , R , Nordström , D , Aaltonen , K , Gudbjornsson , B , Love , T J , Aarrestad Provan , S , Sexton , J , Zobbe , K , Kristensen , L E , Askling , J & Dreyer , L 2021 , ' Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study ' , Rheumatology , vol. 60 , no. 8 , pp. 3656-3668 . https://doi.org/10.1093/rheumatology/keaa828 |
op_relation |
https://vbn.aau.dk/da/publications/7ceece47-dc50-491e-9845-b8c0f9016c52 |
op_rights |
info:eu-repo/semantics/closedAccess |
op_doi |
https://doi.org/10.1093/rheumatology/keaa828 |
container_title |
Rheumatology |
_version_ |
1812815177399140352 |